Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
Elizabeth NallyMatthew YoungConnor WellsRory FairheadKatherine BainesHannah Cheney-LoweFrancesca Jackson-SpenceThomas Powles
Published in: European urology focus (2024)
Antibody-drug conjugates have transformed treatment for urothelial cancer (UC). Enfortumab vedotin is the new standard of care in the first-line setting for advanced UC. A personalised approach targeting HER2 in UC is currently being explored.